Since the publication of the February 28 issue of IBO (see IBO 2/28/18), which included estimated figures for the IBO Life Science and Analytical Instrument Indexes (LSA Indexes), quarterly and annual estimates have been finalized for three companies: Bio-Rad Laboratories Life Science, Merck KGaA Life Science and NanoString Technologies. The updated financial results affect the IBO Life […]
Single-digit losses for both Indexes
In what is viewed as a step forward for NGS-based clinical testing, the US Centers for Medicare & Medicaid Services (CMS) announced this month a final National Coverage Determination (NCD) for FDA-approved NGS tests for advanced cancer (defined as either recurrent, relapsed, refractory, metastatic, or advanced stages III or IV) patients as long as certain […]
Latest sales, operating income and net profit figures for analytical instrument and laboratory product companies
Experts in academia, cancer research and the pharmaceutical industry have been voicing concerns over the spike of clinical trials for cancer immunotherapies, believing that many of the trials will not be completed due to a lack of participants. The increase in trials has resulted in duplicate trials being conducted, which are using up resources that […]
Modular systems prove popular
Business and government spending inch up
Latest purchase to boost distribution and QC capabilities
New investments in manufacturing and R&D promised
Technology will benefit from FBI investment
Pay Invoice
Latest Blogs
-
Lab Instrument Sales in China Collapse
March 29, 2024 1:15 pm
-
Pittcon 2024 Comes to San Diego
February 14, 2024 1:10 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
